Accelerate Diagnostics, Inc AXDX
We take great care to ensure that the data presented and summarized in this overview for Accelerate Diagnostics, Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in AXDX
Top Purchases
Top Sells
About AXDX
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
Insider Transactions at AXDX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 03
2024
|
Jack W Schuler Director |
SELL
Open market or private sale
|
Indirect |
200,000
-2.35%
|
$200,000
$1.57 P/Share
|
|
Dec 03
2024
|
John Patience Director |
BUY
Open market or private purchase
|
Indirect |
200,000
+23.44%
|
$200,000
$1.57 P/Share
|
|
Jun 28
2024
|
Jack W Schuler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,737
+18.98%
|
-
|
|
Jun 28
2024
|
Louise Francesconi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,737
+12.37%
|
-
|
|
Jun 28
2024
|
Hany Massarany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,737
+11.38%
|
-
|
|
May 31
2024
|
Wayne Burris Director |
BUY
Exercise of conversion of derivative security
|
Direct |
839
+33.33%
|
-
|
|
May 29
2024
|
Hany Massarany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,894
+19.71%
|
-
|
|
May 29
2024
|
Jack W Schuler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,894
+33.76%
|
-
|
|
May 29
2024
|
Jennifer Regan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,631
+38.64%
|
-
|
|
May 29
2024
|
Louise Francesconi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,894
+21.5%
|
-
|
|
May 20
2024
|
Jack W Schuler Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,560,694
+15.5%
|
-
|
|
May 20
2024
|
Larry Michael Mertz Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
361
-0.22%
|
$0
$0.88 P/Share
|
|
May 20
2024
|
Larry Michael Mertz Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,283
+0.77%
|
-
|
|
Apr 17
2024
|
Jack Phillips Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
26,735
-14.1%
|
$0
$0.78 P/Share
|
|
Apr 17
2024
|
Jack Phillips Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
59,928
+24.01%
|
-
|
|
Apr 12
2024
|
Jack Phillips Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
26,545
-16.99%
|
$0
$0.86 P/Share
|
|
Apr 12
2024
|
Jack Phillips Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
59,928
+27.72%
|
-
|
|
Apr 09
2024
|
Larry Michael Mertz Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
13,984
-14.71%
|
$0
$0.87 P/Share
|
|
Apr 09
2024
|
Larry Michael Mertz Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,633
+29.94%
|
-
|
|
Apr 09
2024
|
David Patience Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,296
-20.87%
|
$0
$0.87 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 2.75M shares |
|---|---|
| Exercise of conversion of derivative security | 291K shares |
| Open market or private purchase | 347K shares |
| Open market or private sale | 299K shares |
|---|